SELLAS Life Sciences says pivotal Phase 3 REGAL study of Galinpepimut-S in AML surpasses pre-specified 80th event

SELLAS Life Sciences announced its pivotal Phase 3 REGAL registrational trial of Galinpepimut-S (GPS) as maintenance therapy in acute myeloid leukemia patients who achieved complete remission after second-line antileukemic therapy has surpassed the pre-specified 80th clinical event.

Detected & updated continuously · Source: Nebula